Q-omics provides the consensus-scored C3orf20 profile across patient tissues and cancer cell-line models. C3orf20 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, C3orf20 is differentially expressed in 6, with the highest sampling consensus in THCA. Additionally, C3orf20 RNA expression shows 16,979 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, THCA, and THYM as cancer lineages where C3orf20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C3orf20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C3orf20 survival associations across molecular data types. C3orf20 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C3orf20 RNA expression–survival associations across cancer types. High C3orf20 expression shows unfavorable associations in LUSC, but favorable associations in HNSC, SCLC, UCS, READ and LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for C3orf20 RNA expression.
This table summarizes C3orf20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for C3orf20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C3orf20 shows lower tumor expression in THCA, KIRP, COAD, KICH and LUSC and higher tumor expression in BLCA. The THCA box plot shows higher C3orf20 RNA expression in normal versus tumor tissue (log2 FC = −0.285, t-test p < 0.001).
This table shows molecular features associated with C3orf20 in patient tissues and cancer cell lines. In patient samples, C3orf20 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, C3orf20 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Lymphoma.
